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It has been hypothesized that environmental estrogens may play a role in the increasing
incidence of breast cancer, testicular cancer, and other problems of the reproductive system.
While a single causal agent can be identified in cases in which humans have had occupational
exposures, wildlife showing signs of reproductive damage have usually been exposed to a
combination of endocrine disruptors that may act cumulatively. The development of appropriate
biomarkers of cumulative exposure, and their measurement at developmental points where
exposure is critical, are required to test the environmental estrogen hypothesis. Measuring levels
of each of the xenoestrogens in blood is a better approximation of real exposure at the target
organ level than inferring cumulative exposure by estimating from mass balance of dietary levels.
However, the cumulative estrogenicity of mixtures cannot be directly concluded from individual
xenoestrogen plasma levels. Twoapproaches may be used to assess total load: a) the development
of methods to study mixtures of these xenoestrogens, to quantify their cumulative effects, and to
begin to understand their interactions (i.e., additivity, synergy, antagonism, or independent
action), so that plasma concentrations may be translated into units of activity such as "estradiol
equivalents"; and b) the development of methods to separate xenoestrogens from ovarian
estrogens in blood and to directly measure the estrogenic activity of the xenoestrogen extract
using a bioassay. The cumulative activity may be used as a marker of exposure to xenoestrogens.
This article reports the development of a method to extract and separate xenoestrogens from
ovarian estrogens using human serum as a source, followed by using a bioassay for determination
of the cumulative xenoestrogen load as "estradiol equivalents." Environ Health Perspect
105(Suppl 3):647-654 (1997)
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Introduction
Xenoestrogens include several lipophilic, biphenyl (PCB) congeners. More recently,
persistent compounds to which humans nonchlorinated compounds used as antiox-
and wildlife have been exposed. Among idants and plasticizers were found to be
these synthetic chemicals are a number of estrogenic (1-3). The detrimental effects
chlorinated organics, such as the insecti- ofenvironmental exposure to xenoestrogens
cides kepone, dieldrin, DDT and its are evident when observing the abnormal
metabolites, and some polychlorinated development ofthe reproductive system in
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gull embryos exposed in ovo to DDT and
otherpesticides (4). Similarly, the decreased
reproductive success ofalligators and tur-
tles in Lake Apopka, Florida, was linked to
a spill ofkelthane, a pesticide formulation
containing DDE (5). Other evidence that
certain chemicals acted as endocrine dis-
ruptors was revealed when various occupa-
tional exposures in humans were reported.
In 1949, aviation crop dusters handling
DDT were found to have reduced sperm
counts (6). While a single causal agent can
be identified in cases in which humans
have had occupational exposures, wildlife
showing signs ofreproductive damage are
usually exposed to a combination of
endocrine disruptors. Additionally, some of
these chemicals may traverse the human
placenta and have the potential to
adversely affect the developing fetus (7).
Although some of these effects may be
obvious upon birth, others may not mani-
fest themselves until sexual maturity has
been reached. For example, boys exposed
in utero to PCBs appeared normal during
childhood, but at puberty their penises
were significantly smaller than those of
nonexposed controls (7).
It has been hypothesized that environ-
mental estrogens may play a role in the
declining quantity and quality ofhuman
semen during the last 50 years, as well as in
the increased incidence oftesticular cancer
and cryptorchidism in males and breast
cancer incidence in both females and
males in the industrialized world (8-10).
Regarding breast cancer, the main risk fac-
torfor its development is exposure to estro-
gens throughout an entire lifetime (11).
Moreover, increased plasma levels of"bio-
available" ovarian estrogens (not bound to
sex hormone-binding globulin [SHBG]) in
postmenopausal women correlate positively
with breast cancer (12).
Among the estrogenic xenobiotics,
PCBs and DDT were considered suitable
markers of exposure for breast cancer
because they were released massively into
the environment beginning approximately
50 years ago and they are persistent; their
presence in serum may represent cumula-
tive exposure during a lifetime. Three
recent studies showed a correlation between
the occurrence ofbreast cancer and levels of
xenoestrogens. Wolffet al. (13) found that
serum DDE levels correlated with breast
cancer incidence in a study of 58 breast
cancer patients and 171 controls that were
well matched for risk factors and age.
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Another study documented that estrogen-
receptor positive breast cancer correlated
with higher concentrations ofDDE in their
tissues (14). Krieger et al. (15) studied 150
women with breast cancer and 150 controls;
each set consisted of 50 African-American,
50 Caucasian, and 50 Asian-American
women. When the data from all ethnic
groups were pooled, no significant correla-
tion was observed between plasma levels of
DDE and breast cancer (15). However,
when the cases and matching controls were
evaluated separately, according to their eth-
nic group, high serum DDE levels were cor-
related with breast cancer incidence in
Caucasian and African-American women
but there was no significant correlation in
Asian-American women. Evidence ofa link
between exposure to PCBs and breast cancer
incidence is equivocal (16). However, these
studies correlated exposure to total PCBs,
ratherthan to thelevels ofspecific congeners.
Epidemiological studies should be
conducted involving larger sample sizes to
clarify the relevance of these findings. It
would be impractical to test only for the
presence of DDT metabolites and PCBs
since not all the PCB congeners are estro-
genic, and many other environmental estro-
gens may also play a role. The newly
identified estrogens may be less persistent
than PCBs and DDT metabolites; however,
they are widely used and exposure may
occur steadily due to their presence in foods
(3). Measuring the levels of each of the
xenoestrogens in blood is a better approxi-
mation ofreal exposure at the target organ
level than inferring cumulative exposure
from estimation ofmass balance ofdietary
levels. However, cumulative estrogenicity of
mixtures cannot be directly deduced from
individual xenoestrogen plasma levels. Two
approaches may be used to assess total load:
a) the development ofmethods to study
mixtures ofthese xenoestrogens in order to
quantify their cumulative effects and to
begin to understand their interactions (i.e.,
additivity, synergy, antagonism, or inde-
pendent action), so that plasma concentra-
tions maybe translated into units ofactivity
such as "estradiol equivalents," and b) the
development ofmethods to separate xenoe-
strogens from ovarian estrogens in blood
and directly measure the estrogenic activity
ofthe xenoestrogen extract using a bioassay.
This cumulative activity may be used as a
marker ofexposure to xenoestrogens.
This article describes the extraction and
separation ofxenoestrogens from ovarian
estrogens and phytoestrogens using human
serum as a source. Next, methodologies to
determine the effect ofxenoestrogen mix-
tures by means ofthe E-SCREEN bioassay are
presented. This bioassay measures the pro-
liferative effect ofestrogens on their target
cells. The proliferative effect ofxenoestro-
gens is expressed as "estradiol equivalents."
Materials and Methods
Chemicals
Estradiol-17P (E2) was obtained from
Calbiochem (Richmond, CA). DDT
(technical grade), o,p'-DDT, p,p'-DDT,
o,p'-DDD, p,p'-DDD, p,p'-DDE, a PCB
congener (2,2'3,3'6,6'-hexachlorobiphenyl
[2,2',3,3',6,6'-HCB]), o-phenylphenol,
m-phenylphenol, p-phenylphenol, and ben-
zylbutylphthalate were from Ultra Scientific
(North Kingstown, RI). Bisphenol-A was
purchased from Aldrich Chemical Co.
(Milwaukee, WI). Each ofthese chemicals
was dissolved in ethanol or dimethyl sulf-
oxide (DMSO) before being tested in the
various assay systems. The final solvent con-
centration in culture medium did not
exceed 0.1%; this did not affect cell yields.
The organic solvents, hexane, methanol,
and 2-propanol were all ofhigh-perfor-
mance liquid chromatography (HPLC)
grade and were purchased from Fisher
Scientific (Pittsburgh, PA). Ethanol and
ethyl ether were from Sigma Chemical Co.
(St. Louis, MO) and petroleum ether was
from Aldrich Chemical Co. (Milwaukee,
WI). All other chemicals were ofthe highest
quality availablefrom commercial sources.
Plasma-derivedandBlood-derived
Human Serum
Plasma-derived human serum was prepared
from outdated plasma supplied by the New
England Medical Center Blood Bank.
Calcium chloride was added to a final con-
centration of 30 mmol/liter to facilitate
clot formation. Blood-derived serum was
from blood samples obtained from healthy
adult volunteers according to a protocol
approved by the Human Investigation
Review Committee at Tufts-New England
Medical Center. After donation, blood was
allowed to clot in glass centrifuge tubes for
2 to 4 hr to obtain serum. Plasma- and
blood-derived sera were clarified by cen-
trifugation (2000xgfor 10 min), stripped
with charcoal-dextran (CD), and stored in
glass tubes at-20°C until use.
RemovalofSexSteroidsbyCharcoal-
DextranTreatmentofSerum
Charcoal (Norit A, acid washed; Sigma)
was washed twice with cold, sterile water
immediately before use. A 5% charcoal-
0.5% dextran T70 (Pharmacia-LKB,
Uppsala, Sweden) suspension was pre-
pared. CD suspension aliquots ofa volume
similar to that of serum aliquots to be
processed were centrifuged at 100xgfor 10
min. Supernatants were aspirated and
serum aliquots were mixed with the char-
coal pellets. This charcoal-serum mixture
was maintained in suspension by rolling at
4 cycles/min at 370C for 1 hr. This suspen-
sion was centrifuged at 2000xgfor 20 min.
The supernatant was then filtered through
a Nalgene filter with a pore size of 0.45
pm. More than 99% ofserum sex steroids
were removed by this treatment, as mea-
sured by removal of3H-estradiol (17);
estradiol concentrations after CD treat-
ment were less than 0.01 pg/ml as mea-
sured by radioimmunoassay. CD-treated
sera were stored at -20°C until needed.
Samples kept in the freezer for 1 year
maintained their inhibitory properties on
the proliferation ofhuman estrogen-sensi-
tive breast tumor MCF-7 cells; plasma- and
blood-derived sera were equallyeffective.
BioaayforMeasuringEstogenicity
Theoretical underpinnings ofthe E-SCREEN
assay have been published elsewhere
(17,18). Cloned MCF-7 cells were trypsi-
nized and plated into 12-well plates
(Falcon, Lincoln Park, NJ) at initial con-
centrations of30,000 cells perwell (19,20).
Cells were allowed to attach for 24 hr; then
the seeding medium (5% fetal bovine
serum in Dulbecco's modified Eagle's
medium [DMEM]) was replaced with the
experimental medium [5% CD-treated
human serum supplemented to phenol red-
free DMEM (CDHuS)]. A range of con-
centrations of the test compounds was
added to this medium. The bioassay was
terminated on day 6 (late exponential
phase) by removing the media from the
wells, adding a cell-lysing solution (10%
ethylhexadecyl-dimethylammonium bro-
mide [Eastman Kodak Co., Rochester, NY]
in 0.5% Triton X-100, 2 mM MgCI2, 15
mM NaCl, 5 mM phosphate buffer, pH
7.4) and counting the nuclei in a Model
ZM Coulter Counter Apparatus (Coulter
Electronics, Hialeah, FL).
The best estimate ofthe proliferative
behavior of a cell population is doubling
time (tD); the time interval in which an
exponentially growing culture doubles its
cell number. Determining tD requires mea-
suring cell yields at several time intervals
during the exponential proliferation phase.
Aless cumbersome alternative to measuring
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proliferation rates is to compare the cell yield
achieved by similar cell inocula harvested
simultaneously during the late exponential
phase ofproliferation. The proliferative
effect is measured as the ratio ofthe highest
cell yield obtained with the test chemical to
the hormone-free control. Under these
experimental conditions, cell yield repre-
sents a reliable estimate ofthe relative pro-
liferation rate achieved by similar inocula
exposed to different proliferation regulators.
In our experimental design, MCF-7 cell
yields were measured 6 days after to; how-
ever, significant differences between control
and estrogen-treated cultures are already
apparent after 4 days (21).
The estrogenic activity ofxenobiotics
was assessed by determining relative prolif-
erative potency (RPP); this is 10Ox the
ratio between the minimal concentration
ofestradiol needed for maximal cellyield at
6 days and the minimal dose of the test
compound needed to achieve a similar
effect, and by measuring relative prolifera-
tive effect (RPE); this is 10Ox the ratio
between the highest cell yield obtained
with the chemical and with estradiol. The
RPE indicates whether or not the com-
pound being tested induces a proliferative
response quantitatively similar to the one
obtained with E2, that is, a full agonist
(RPE= 100), or a proliferative yield signifi-
cantly lower than the one obtained with
E2, that is, a partial agonist. When com-
bined with estradiol, antagonists signifi-
cantly lower the proliferative yield obtained
with estradiol alone.
AntagonisticEffect
The E-SCREEN bioassay was also used to
evaluate possible antagonistic activity of
xenobiotics used in the cumulative effect
experiments. Bisphenol-A (BPA) and p,p'-
DDE were tested at a range of concentra-
tions with and without the addition of 100
pM estradiol. The proliferative yield was
compared to the steroid-free control. The
differences between the estradiol-treated
groups were assessed by a posteriori Shaffe's
test (22). Ap value of <0.05 was regarded
as significant. Results were expressed as
mean ratio ofproliferative yield to steroid-
free control ± SE. Benzylbutylphthalate
(BBP) and 2,2',3,3',6,6'-HCB were also
tested using the same method.
AMethod to DetermineCumulaive
Effecs ofXenoestrogens
The E-SCREEN bioassay was used to
evaluate the cumulative effect offour xeno-
biotics: benzylbutylphthalate, bisphenol-A,
p,p'-DDE, and 2,2',3,3'6,6'-HCB. Each of
these xenoestrogens was tested for prolifera-
tive response at a range ofconcentrations
from 10 pM to 100 pM. From these dose-
response curves, a minimal proliferative
concentration was determined for each
chemical. The xenobiotics, in three- and
four-component mixtures, were combined
at the minimal effective dose that produced
a proliferative effect. Proliferative yield
results, obtained from the mean cell num-
ber, were normalized to the steroid-free
control to correct for differences in the ini-
tial plating density. These results were then
converted to estradiol equivalents (EEqs),
an activity unit representing xenoestrogen
proliferative effect. The normalized mean
cell number was used to interpolate EEqs
from a normalized estradiol response curve.
The minimal detectable EEq from the
E-SCREEN bioassay was determined by
t-test. Apvalue <0.05 was regarded as sig-
nificant. The measured mixture EEqs were
compared with calculated EEqs. Calculated
EEqs for the mixtures were determined by
adding the measured EEqs ofthe individual
xenobiotics. The calculated EEqs for the
mixtures represent the expected proliferative
effect in the case ofthe three or fourxenobi-
otic combinations interacting in an additive
manner. Differences between the measured
and calculated EEq values were assessed
using chi-square analysis. Ap value <0.05
was regarded as significant. The results
were expressed as EEqs ± SD. The cumula-
tive effect experiments were conducted in
duplicated wells and repeated 4 times.
Extration ofXenoestrogens
fromPlasma-derived Serum
andExtrac Cleanup
Extraction ofxenoestrogens from serum
was performed as described by Burse et al.
(23), with modifications (1). To develop
the extraction procedure, CD-serum was
used for spiking and as a "blank" prepara-
tion. The extracts from the "blank" prepa-
rations are devoid of absorbance at 280
nm, and therefore do not interfere with the
quantification ofadded xenoestrogens. In
addition, CD-treated serum is lacking in
estrogenic activity; this also holds for quan-
titation ofthe spiked estrogen by means of
the E-SCREEN bioassay. To assess the recov-
ery ofxenoestrogens from serum, 4-ml
aliquots ofCD-treated serum were spiked
with a known amount ofstandard xenoe-
strogen and allowed to equilibrate for 2 hr
at room temperature.
Sample Extraction. Methanol (2 ml)
was added to each oftwo 4-ml aliquots of
serum, mixed by vortexing, and then 5 ml
of hexane: ethyl ether (1:1, by vol) was
added to extract the mixture. The mixture
was first agitated on a rotary mixer for 15
min and then centrifuged at 2000xgfor 5
min. The organic phase was collected, and
the aqueous phasewas extracted twice more.
The organic phases were pooled and subse-
quentlyconcentrated to 1 ml byevaporation
undera nitrogen stream.
Acid Cleanup ofthe Organic Phase
Prior to HPLC. Concentrated sulfuric
acid (0.5 ml) was added to the concen-
trated 1-ml sample oforganic phase. The
sample was briefly vortex-mixed and then
centrifuged for 5 min at 2000xg. The
organic phase was collected and the aque-
ous phase was extracted twice more with
1 ml ofhexane. The organic phases were
pooled and dried completely under nitro-
gen. The sample was resuspended in
hexane and then injected into HPLC.
HPLCAnalysis/Sample Preparation
for Measuring Estrogenic Activity by
Bioassay. Separation was performed by the
method described by Medina and Sherman
(24), modified by Sonnenschein et al. (1)
in a Kratos chromatographer (solvent deliv-
ery system: Spectroflow 400; gradient con-
troller and absorbance detector: Spectroflow
783; injector/mixer: Spectroflow 491; all
from ABIAnalytical, Inc, Santa Clara, CA).
Aliquots of 500 pll were injected into a 4x
220 mm Spheri 5 silica column (Brownlee
Labs, ABI) equilibrated with 100% n-
hexane. Xenoestrogens were eluted by a gra-
dient oftwo mobile phases: n-hexane (phase
A), and n-hexane:methanol:2-propanol,
(40:45:15 byvol) (phase B) at a flow rate of
1.5 ml/min and a pressure of 5x 10- pas-
cals (Pa). The gradient was developed as
follows: after injection, 100% phase A
flowed for 2 min; then, the concentration
ofphase B increased from 0 to 400 ml/liter
in 15 min and from 400 to 1000 ml/liter in
the next 10 min. The elution profile was
monitored at 280 nm with a Kratos
Spectroflow 783 detector. All testedxenobi-
otics eluted during the first 10 min (1);
they were evaporated completely and resus-
pended in ethanol. In the pilot experiment
reported herein, the HPLC fractions from
two 4-ml extracts were combined and resus-
pended in 140 pl. This was done to allow
for monitoring recoveries ofspiked chemi-
cals and proliferative activities in replicates.
The efficiency ofthe step to solubilize xeno-
estrogens eluted from the HPLC column
was testedbyHPLC (percentrecovery).
After these steps had been performed,
100 pl ofthe remaining resuspended eluate
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was pipetted into 9.9 ml ofthe CD-treated
culture medium (5% CD-treated human
serum). This sample is designated "undi-
luted preparation," and from it, the serial
2-fold dilutions were made; 1:1, 1:4, 1:8,
1:16, and 1:32. After equilibration at room
temperature for 20 min, the preparation
was rendered sterile by filtration through a
0.22 pm (pore size) membrane. The dilu-
tions were assayed by the E-SCREEN test. A
"blank" was prepared from CD-treated
human serum by following the fractiona-
tion protocol that was described for the
preparations spiked with known amounts
ofxenoestrogens.
Quantafication. To obtain calibration
curves, chemicals to be analyzed were
injected at five to seven different doses,
ranging from 0 to 500 nmol. The correla-
tion coefficient for each curve was 0.99.
Results
IdentificationofXenoestrogens
bytheE-SCREENAssay
The three isomers ofphenylphenol, DDT
(technical grade), and DDT metabolites
were tested for estrogenicity (Table 1).
Among the three isomers ofphenylphenol,
p-phenylphenol was a full agonist and the
most potent (RPE = 88, RPP = 0.001);
o-phenylphenol was the least potent and a
partial agonist (RPE= 30, RPP = 0.0001).
The meta isomer was also a partial agonist;
its potency fell within the other two
(RPE=60, RPP =0.0002).
o,p'-DDT, o,p'-DDD, andp,p'-DDT
were full agonists; meanwhile p,p'-DDE,
andp,p'-DDD were partial agonists. DDT
(technical grade) was a full agonist; this
was expected since it consists of 20% of
o,p'-DDT and 80% ofp,p'-DDT.
In testing for antagonistic effects,
BPA (a full agonist) did not alter the pro-
liferative effect of estradiol (Figure 1).
BBP and 2,2',3,3',6,6'-HCB were also
tested; they had no antagonistic effect
(data not shown). The partial agonist
p,p'-DDE showed statistically significant,
partial antagonistic effects on MCF-7 cell
proliferation (Figure 1).
DevelopmentofaMethodto Reveal
Cumulative Effects ofXenoestrogens
The firststep toward this endwas to evaluate
the sensitivity of the E-SCREEN test by
means ofa detailed estradiol dose-response
curve (Figure 2). At any concentration
below 1 pM (1 fmol in 1 ml culture
medium), the mean cell number did not
differ significantly from the steroid-free
Table 1. Estrogenic effect of industrial chemicals mea-
sured bythe E-SCREEN assay.
RPE, RPP,
Compound Concentrationa %b %C
Estradiol 100 pM 100 100
4-Phenylphenol 10 pM 88 0.001
3-Phenylphenol 50 pM 60 0.0002
2-Phenylphenol 100 pM 30 0.0001
Benzylbutylphthalate 10 pM 90 0.001
Bisphenol-A 1 pM 82 0.01
2,2',3,3',6,6'-HCB 10 pM 62 0.001
DDTd 10pM 80 0.001
o,p'-DDT 10pM 86 0.001
p,p'-DDT 10pM 71 0.001
p,p'-DDE 10 pM 25 0.001
o,p'-DDD 10 pM 73 0.001
p,p'-DDD 10pM 19 0.001
alndicates the lowest concentration needed for maxi-
mal cell yield. bRelative proliferative effect (RPE) is cal-
culated as 100x(PE-1I of the test compound/(PE-1)qf
E2; a value quantitatively similar to E2 (RPE=100) indi-
cates that the compound tested is a full agonist, a
value of 0 indicates that the compound lacks estro-
genicity at the doses tested, and a value significantly
lower than E2 (RPE=100) suggests that the xenobiotic
is a partial agonist. cRelative proliferative potency
(RPP) is the ratio between E2 and xenobiotic doses
needed to produce maximal cell yields xlOO. All com-
pounds designated as full or partial agonists (RPE>15)
increased cell yields significantly over the hormoneless
control (p<0.05). dTechnical grade.
control (p< 0.05 as determined by the
t test). Therefore, 1 fmol ofestradiol/well
was determined as the lowest detectable
estrogen amount in this assay. Mixtures of
xenoestrogens were prepared to assess their
cumulative effect. Each xenobiotic was set
at a dose which would yield the minimal
proliferative effect (the equivalent to 1
fmol estradiol). The xenobiotics BBP,
2,2',3,3',6,6'-HCB, BPA, and p,p'-DDE
were combined in three and four compo-
nent mixtures. Cell numbers were converted
to estradiol equivalents by interpolation on
the estradiol dose-response curve (Table 2)
(measured cumulative effect). The effect of
each xenoestrogen in the mixture was esti-
mated; cell yields were converted to estra-
diol equivalents. These values were added
to calculate the expected estrogenic effect
of the mixture. Table 2 shows that the
measured cumulative effects are signifi-
cantly different from the expected values
(p < 0.05 as determined by chi-square
analysis). This suggests that the cumulative
effect ofthese xenoestrogens is synergistic
rather than additive (Figure 3).
TestingtheEstrogenicActivity
ExtractedfromPlasma-derived Serum
To measure the estrogenic effect of the
spiked extracts, dose-response curves to
1200
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Figure 1. Antagonistic effects of p,p'-DDE and
bisphenol-A. Cells were harvested after 6 days of
exposure. Ordinate: cell number expressed as the
treated/control ratio x100; abscissa: concentration.
Data points represent the mean of four experiments;
error bars represent SE. Bisphenol-A was tested with
(U) and without (E) 100 pM E2. Shaffe's test showed
no significant differences between the two treatment
groups. p,p'-DDE was tested with (A) and without (A)
100 pM E2. Shaffe's test revealed significant differ-
ences between the two treatment groups (p<0.05).
-50 0600-
400-
200-
0
0.1 1 10 100 1,000 10,000
Femtomol/well
Figure 2. Dose-response curve of estradiol. Cells
were harvested after 6 days of exposure. Ordinate: cell
number expressed as the treated/control ratio x100;
abscissa: concentration. Data points represent the
mean of four experiments; error bars represent SD.
t-test revealed significant differences between 1 fmol
of E2 and the control (p<0.05).
estradiol (Figure 4A) and o,p'-DDT
(Figure 4B) were performed simultaneously
with the E-SCREEN test ofthe extracts. The
various dilutions ofblank extracts obtained
from CD-treated serum were assayed to
assess whether toxic or spurious estrogenic
activity was acquired during sample prepa-
ration. The cell yields were similar to those
obtained when similar inocula were grown
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Table 2. Cumulative effects of a mixture offourxenobiotics.
BBP, BPA, pp'-DDE, 2,2',3,3',6,6'-HCB, Mean cell #/ Calculated Measured
PM PM PM pM % control±SD EEq EEq
O 0 0 0 100± lOa - 0
2 0 0 0 127±49 - 1.0
0 0.05 0 0 122 ± 18 - 1.0
0 0 2 0 125± 12 - 1.0
0 0 0 0.5 108 ± 10 - 1.0
2 0.05 2 0 271 ±49 3.0 8.0
2 0.05 0 0.5 290 ± 68 3.0 9.0
2 0 2 0.5 256 ±46 3.0 7.3
0 0.05 2 0.5 242 ± 30 3.0 6.6
2 0.05 2 0.5 329±49 4.0 12.0
Cells were harvested after 5 days ofexposure. BBP at 2 pM, BPA at 0.05 pM, p,p'-DDE at 2 pM, and 2,2',3,3',6,6'-
HCB at 0.5 pM induce the minimal proliferative effect of 1 fmol of EEqs. EEqs ofthe xenobiotics were interpolated
from the E2 dose-response curve (Figure 2) using normalized mean cell number of four experiments ± SD.
Calculated EEqs were determined by adding the EEqs of the mixture components. Measured EEqs were interpo-
lated from E2 dose-response curve (Figure 2) using the normalized mean cell number of four experiments ± SD.
The calculated and measured EEqs for each mixture were significantly different using chi square analysis (p<0.05).
"Negative control: cell yield in 50 ml/literCD-treated serum alone.
I
T
a
T
T
0 A B C D ABC ABD ACD BCD
Figure 3. Cumulative effects of a mixture offour xenobiotics. Cells were harvested after 6 days of expo
points represent the mean of four experiments; error bars represent SD. BBP (A) at 2 pM, BPA (B) al
p,p'-DDE (C) at 2 pM, and 2,2',3,3',6,6'-HCB (D) at 0.5 pM induce the minimal proliferative effect of 1 fm
EEqs of the xenobiotics were interpolated from the E2 dose-response curve (Figure 2) using the mean cl
of four experiments. Calculated EEqs (solid bar) were determined by adding the EEqs of the mixture co
Measured EEqs (shaded bar) were interpolated from E2 dose-response curve (Figure 2) using the mean c
of four experiments. The calculated and measured EEqs for each mixture were significantly different
square analysis (p<0.05).
in the presence of 5% CD-treated serum,
indicating the absence ofestrogenic activity
(Figure 5A). Microscopic observation did
not reveal any toxic effects. Additionally, a
full estrogenic response was obtained when
100 pM estradiol was added to this prepa-
ration (Figure SA). The spiked serum
extract was also tested at various dilutions.
The recovery ofspiked o,p'-DDT was 84%
(83 and 85%). Thus, the most concen-
trated dilution ("undiluted") was approxi-
mately 12 pM. As shown in Figure SB,
the dilution curve ofthe spiked preparation
is in agreement with the dose-response
curve to o,p'-DDT added directly to 5%
CD-treated human serum supplemented
medium in Figure 4B. Lack oftoxic activ-
ity in this extract is demonstrated by maxi-
mal estrogenic activity when each dilution
of the spiked extract was tested in the
presence of 100 pM estradiol (Figure 5B).
Discussion
In addition to being exposed to their own
steroidal estrogens, humans and wildlife are
also exposed to synthetic xenoestrogens
(pesticides, plasticizers, antioxidants, etc.)
and natural ones, such as phytoestrogens.
Exposure to synthetic estrogens, such as
DDT, produces adverse effects in wildlife
and humans. The lack ofdeleterious effects
ofphytoestrogens on human health may be
explained by adaptive phenomena that
developed slowly during the coevolution of
plants and mammals. Sudden exposure of
organisms to phytoestrogens that are for-
eign to their natural ecosystems may result
in deleterious health effects (25). The role
of the different estrogens (endogenous,
synthetic, and phytoestrogens) in the etiol-
ogy ofcancer incidence and reproductive
disorders awaits further, rigorous epidemi-
ological studies that would correlate expo-
sure to each type of estrogen with their
subsequent health effects.
In this article, we evaluate the concept
of measuring xenoestrogen exposure in
humans by separating xenoestrogens from
endogenous estrogens in human plasma or
serum, and by measuring the combined
estrogenicity of these xenoestrogens by
means ofa bioassay using estrogen-target
cells in culture.
Evaluation ofBioassays to
MeasureEstrogenicActivity
The hallmark ofestrogen action is consid-
ered to be the ability ofestrogens to induce
proliferation of their target organs (26).
Thus, a bioassay that measures cell prolifer-
ation as the end point is the most reliable
assay to assess estrogenicity. The exposure
of male birds, amphibians, and fish to
nongonadal estrogens is well documented
since the egg yolk protein vitellogenin is
induced by estrogen in the liver, and its
ABCD presence can be detected in blood. The
sure. Data presence ofvitellogenin in the plasma of
t0.05 pM, males or females whose reproductive tracts
ol of EEqs. should be dormant is indicative ofexpo-
ell number sure. However, this marker cannot be used
)mponents. in reproductively active females since ovar-
:ell number ian estrogens will induce vitellogenin and
t using chi thus obscure the contribution ofxenoestro-
gens to vitellogenin plasma levels. An
equivalent marker ofexposure has not yet
been found in mammals.
Uterotropic assays measure increases of
uterine wet weight, which are due to the
additive effect of cell proliferation, hyper-
trophy, and water imbibition. While cell
proliferation of the genital tract is specifi-
cally induced by estrogens, different end
points are affected by hormones other than
estrogens (3). Most estrogens produce sim-
ilar effects in different species. However,
tamoxifen is a full agonist in mice and a par-
tial agonist and antagonist in rats and in
human target cells (27). This may explain
the discrepancy regarding the designation of
some DDT metabolites as being estrogenic.
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Figure 4. Dose-response curves of (A) estradiol and (B) o,p'-DDT on MCI
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target-organ level, since no false positives
or negatives have been observed among the
estrogens and nonestrogens tested thus far.
NovelXenoestogens Identified
by the E-SCREENAssay
Many chemicals that are present in our
environment are estrogenic (19,33).
Phenylphenol is one of the top 10 active
ingredients in household pesticides and is
the second most widely used ingredient for
indoor applications (34). We reported pre-
viously that p-phenylphenol is a full estro-
gen agonist (20); o- and m-phenylphenol
are partial agonists (Table 1). o-Phenyl-
phenol is used in the rubber industry, in
Concentration, LM agricultural fungicides, and in disinfec-
F7 cells in culture. Cells were harvested tants; p-phenylphenol is used in the rubber
Data points represent the mean for a set industry and in the manufacture ofresins.
Id in 50 ml/liter CD-treated serum alone. There has been controversy regarding
which DDT metabolites are estrogenic, and
also their relevance to breast cancer inci-
dence (28). The E-SCREEN assay revealed
that all the assayed metabolites are estro-
genic. Additionally, full agonists are devoid
of antagonistic effects (Figure 1); partial
agonists are also partial antagonists (Figure
1). The antagonistic activity ofthese com-
pounds, although statistically significant, is
biologically marginal (Figure 1).
Cumulative Effects
0 1-1
Undiluted 1:1 Undiluted 1:1 1:4 1:8 1:16 1:32
Dilutions
1:4 1:8
Dilutions
Figure 5. Bioactivity of serum extracts on MCF-7 cell proliferation: dose-response curves of serial dil
blank extract from CD-treated serum and (B) CD-treated serum spiked with o,p'-DDT. The ordinate re
yield after6 days in culture. Data points represent the mean for a set offour experiments; error bars r
(o) Blank extract. (0) Blank extract supplemented with 100 pmol/liter estradiol. (A) Extract from CD-<
with 25 pmol/liter o,p'-DDT. (A) Extract from CD-serum spiked with 25 pmol/liter o,p'-DDT supple
100 pmol/liter estradiol. (o) Negative control: cell yield in 50 ml/liter CD-treated serum alone. (U) Pos
cell yield in 50 ml/liter CD-treated serum plus 100 pmol/liter estradiol.
p,p'-DDE, the persistent, dominant
metabolite of DDT, has been found to be
a partial agonist by the E-SCREEN assay (3)
(Table 1, Figure 1), while it is claimed by
some to be devoid ofestrogenicity in the
rat model (28).
In addition to cell proliferation, other
markers ofestrogenic activity, such as the
PgR assay and pS2 assay in MCF-7 cells,
are adequate for assessing estrogenicity in
humans. Cell proliferation assays are more
sensitive than those that induce gene prod-
ucts (1,29-31). The transfection of the
estrogen receptor into yeast cells r
avehicle in which to test various (
It is expected that the use of repc
coding for an enzyme may result
sensitive and less time-consum
However, the specificity and sen
these methods have yet to be as
In addition, the transport effi
xenobiotics may be different in
human cells (32). Thus, the
assay appears to be the best can
establishing a quantitative sta
estrogenic activity in human ci
Environmental exposures are very different
\S11& ~ > from most occupational exposures in which
one chemical is found to be the causative
agent. In environmental exposures, wildlife
'| and humans are concurrently or sequen-
1:16 1:32 tially exposed to a wide array ofchemicals
from various sources. Simultaneous expo-
lutions of (A)
sure to mixtures may result in additivity,
-presents cell synergism, antagonism, or independent
epresent SD. action. Toxicologists use a toxic equivalency
serum spiked factor model for dose conversion, a model
imented with based on the relative potency of the com-
sitive control: pounds to a standard compound (for exam-
ple, 2,3,7,8-tetrachlorodibenzo-p-dioxin,
the model or standard compound, and its
congeners). This concept assumes that the
may create potency ofthe two compounds is the same,
chemicals. regardless of the dose. Additionally, it
rter genes assumes that the chemicals do not inter-
in a more act (synergism, antagonism). Using the
ing assay. E-SCREEN assay, mixtures of xenoestrogens
isitivity of may be tested, and the effects ofmixtures
;certained. compared to the calculated additive effect
iciency of ofeach compound in the mixture (Table 2,
yeast and Figure 3). The analysis ofthe interaction of
E-SCREEN xenoestrogens in the mixtures ofthree and
ididate for four chemicals indicates that the effect of
indard of the mixture is 2- to 3-fold higher than the
ells at the expected effect, assuming simple additivity.
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This is of concern when deciding how to
measure the cumulative exposure to estro-
gens in plasma, fat, or other biological sam-
ples. Measuring individual xenoestrogens
and calculating cumulative exposure by
deriving it from the relative estrogenic
potency ofeach chemical may underesti-
mate the estrogen load by ruling out syner-
gistic effects. This problem may be obviated
by directly measuring the effect ofthe mix-
ture extracted from the biological specimen
through abioassay.
AMethodforMeasuring
theCumulativeEffectof
Xenoestoens inHman Serum
The extraction/clean-up methodology of
pesticides from human serum, described by
Burse et al. (23) and modified as described
by Sonnenschein et al. (1), also allows
quantitative extraction of more polar
estrogens (from alkylphenols to estradiol).
The method was further modified by
eliminating the step that entailed passing
the sample through a Sep Pak cartridge
(Waters Corporation, Milford, MA), since
it results in coelution ofunknown moieties
somewhat toxic to MCF-7 cells (1). When
the Sep Pak step was eliminated, the toxic
effect disappeared (Figure 5). This method
resulted in 83 to 85% recovery of the
spiked op'-DDT. Moreover, the biological
activity accurately paralleled the dose-
response curve to this chemical. Therefore,
it is now feasible to use this method to
measure, in serum, the cumulative effect of
the xenoestrogens tested thus far, since
theywere separated from ovarian estrogens.
We propose to measure the combined
effect ofthe compounds eluted during the
first 10 min ofour HPLC separation as a
marker of exposure to xenoestrogens.
Estrogenic pesticides, PCBs, hydroxylated
PCBs, phenolic antioxidants, and plasticiz-
ers elute from the HPLC column during
the first 10 min, whereas ovarian estrogens,
phytoestrogens, diethylstilbestrol, and
mycoestrogens are retained for more than
12 min (1). Populations that will be
investigated are not expected to have been
exposed to DES or mycoestrogens. Further
optimization of the HPLC separation
protocols may allow the separation of
phytoestrogens from ovarian estrogens.
The data and analysis presented here
represents an attempt to cope with intensi-
fying demands by the public and regulatory
agencies to rigorously evaluate the role of
xenoestrogens in the increased incidence of
male genital tract anomalies, testicular
cancer, and breast cancer in human popula-
tions. In this article, we use novel extraction
protocols and HPLC to measure the cumu-
lative exposure to xenoestrogens. The full
development ofthis concept into a reliable
method to measure exposure in human
populations will require further validation.
Additional techniques, aimed at identifying
all ofthe individual estrogenic xenobiotics
present in serum samples of people sus-
pected ofbeing exposed, will help in corre-
lating the relative contribution of each
xenoestrogen with the observed health
effect in exposed individuals.
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